Story perspectives

Breakthrough Drug NU-9 Targets Early Alzheimer's Inflammation

12/25/2025

Summary

Story summary

Northwestern University researchers have identified a toxic subtype of amyloid beta oligomers that triggers early inflammation and neuronal dysfunction in Alzheimer's disease.
Their experimental drug NU-9 reduces this harmful subtype and related damage in pre-symptomatic mouse models.
The approach emphasizes early intervention to potentially prevent cognitive decline before symptoms appear.
NU-9 lowers reactive astrogliosis and abnormal TDP-43 levels, indicating potential protection while researchers plan memory and neuron health studies.

1 of 1

Story summary

Northwestern University researchers have identified a toxic subtype of amyloid beta oligomers that triggers early inflammation and neuronal dysfunction in Alzheimer's disease.
Their experimental drug NU-9 reduces this harmful subtype and related damage in pre-symptomatic mouse models.
The approach emphasizes early intervention to potentially prevent cognitive decline before symptoms appear.
NU-9 lowers reactive astrogliosis and abnormal TDP-43 levels, indicating potential protection while researchers plan memory and neuron health studies.